World's Best Scientists 2026 revealed!

D-Index & Metrics

Medicine

D-Index
99
Citations
45818
World Ranking
8468
National Ranking
828

Helen M. Colhoun publication distribution in Medicine in 2026

The chart shows the distribution of publications by all Research.com ranked scientists in the field of Medicine in 2026. The highlighted bar marks where Helen M. Colhoun sits on this spectrum.

101–120 publications: 5 scientists 121–140 publications: 26 scientists 141–160 publications: 73 scientists 161–180 publications: 155 scientists 181–200 publications: 230 scientists 201–220 publications: 363 scientists 221–240 publications: 487 scientists 241–260 publications: 545 scientists 261–280 publications: 722 scientists 281–300 publications: 768 scientists 301–320 publications: 834 scientists 321–340 publications: 895 scientists 341–360 publications: 922 scientists 361–380 publications: 838 scientists 381–400 publications: 861 scientists 401–420 publications: 918 scientists 421–440 publications: 806 scientists 441–460 publications: 771 scientists 461–480 publications: 751 scientists 481–500 publications: 713 scientists 501–520 publications: 617 scientists 521–540 publications: 611 scientists 541–560 publications: 537 scientists 561–580 publications: 504 scientists 581–600 publications: 509 scientists 601–620 publications: 396 scientists 621–640 publications: 386 scientists 641–660 publications: 371 scientists 661–680 publications: 340 scientists 681–700 publications: 336 scientists 701–720 publications: 307 scientists 721–740 publications: 259 scientists 741–760 publications: 230 scientists 761–780 publications: 228 scientists 781–800 publications: 217 scientists 801–820 publications: 204 scientists 821–840 publications: 186 scientists 841–860 publications: 177 scientists 861–880 publications: 155 scientists 881–900 publications: 139 scientists 901–920 publications: 145 scientists 921–940 publications: 116 scientists 941–960 publications: 133 scientists 961–980 publications: 91 scientists 981–1,000 publications: 96 scientists 1,001–1,020 publications: 77 scientists 1,021–1,040 publications: 70 scientists 1,041–1,060 publications: 63 scientists 1,061–1,080 publications: 77 scientists 1,081–1,100 publications: 49 scientists 1,101–1,120 publications: 54 scientists 1,121–1,140 publications: 49 scientists 1,141–1,160 publications: 51 scientists 1,161–1,180 publications: 35 scientists 1,181–1,200 publications: 39 scientists 1,201–1,220 publications: 26 scientists 1,221–1,240 publications: 37 scientists 1,241–1,260 publications: 36 scientists 1,261–1,280 publications: 27 scientists 1,281–1,300 publications: 32 scientists 1,301–1,320 publications: 28 scientists 1,321–1,340 publications: 17 scientists 1,341–1,360 publications: 30 scientists 1,361–1,380 publications: 28 scientists 1,381–1,400 publications: 17 scientists 1,401–1,420 publications: 21 scientists 1,421–1,440 publications: 15 scientists 1,441–1,460 publications: 12 scientists 1,461–1,480 publications: 12 scientists 1,481–1,500 publications: 18 scientists 1,501–1,520 publications: 14 scientists 1,521–1,540 publications: 17 scientists 1,541–1,560 publications: 15 scientists 1,561–1,580 publications: 6 scientists 1,581–1,600 publications: 2 scientists 1,601–1,620 publications: 12 scientists 1,621–1,640 publications: 11 scientists 1,641–1,660 publications: 8 scientists 1,661–1,680 publications: 5 scientists 1,681–1,700 publications: 5 scientists 1,701–1,720 publications: 10 scientists 1,721–1,740 publications: 12 scientists 1,741–1,760 publications: 14 scientists 1,761–1,780 publications: 6 scientists 1,781–1,795 publications: 5 scientists 1,796+ publications: 100 scientists
101 publications 1,796+

This scientist: 438 publications — 47th percentile

47% of scientists in this discipline score the same or lower.

The last bar groups every scientist with 1,796 publications or more.

Helen M. Colhoun D-index placement in Medicine in 2026

The chart shows the D-index (discipline H-index) distribution of Medicine scientists ranked by Research.com in 2026. The highlighted bar marks where Helen M. Colhoun sits on this spectrum.

70–71 D-Index: 226 scientists 72–73 D-Index: 391 scientists 74–75 D-Index: 574 scientists 76–77 D-Index: 730 scientists 78–79 D-Index: 891 scientists 80–81 D-Index: 972 scientists 82–83 D-Index: 1,027 scientists 84–85 D-Index: 1,003 scientists 86–87 D-Index: 960 scientists 88–89 D-Index: 970 scientists 90–91 D-Index: 922 scientists 92–93 D-Index: 839 scientists 94–95 D-Index: 808 scientists 96–97 D-Index: 779 scientists 98–99 D-Index: 668 scientists 100–101 D-Index: 611 scientists 102–103 D-Index: 630 scientists 104–105 D-Index: 513 scientists 106–107 D-Index: 541 scientists 108–109 D-Index: 445 scientists 110–111 D-Index: 429 scientists 112–113 D-Index: 400 scientists 114–115 D-Index: 393 scientists 116–117 D-Index: 318 scientists 118–119 D-Index: 302 scientists 120–121 D-Index: 287 scientists 122–123 D-Index: 255 scientists 124–125 D-Index: 256 scientists 126–127 D-Index: 252 scientists 128–129 D-Index: 230 scientists 130–131 D-Index: 179 scientists 132–133 D-Index: 168 scientists 134–135 D-Index: 163 scientists 136–137 D-Index: 159 scientists 138–139 D-Index: 134 scientists 140–141 D-Index: 134 scientists 142–143 D-Index: 118 scientists 144–145 D-Index: 109 scientists 146–147 D-Index: 106 scientists 148–149 D-Index: 74 scientists 150–151 D-Index: 79 scientists 152–153 D-Index: 80 scientists 154–155 D-Index: 87 scientists 156–157 D-Index: 57 scientists 158–159 D-Index: 74 scientists 160–161 D-Index: 69 scientists 162–163 D-Index: 60 scientists 164–165 D-Index: 53 scientists 166–167 D-Index: 39 scientists 168–169 D-Index: 42 scientists 170–171 D-Index: 32 scientists 172–173 D-Index: 39 scientists 174–175 D-Index: 40 scientists 176–177 D-Index: 28 scientists 178–179 D-Index: 19 scientists 180–181 D-Index: 23 scientists 182–183 D-Index: 31 scientists 184–185 D-Index: 18 scientists 186–187 D-Index: 20 scientists 188–189 D-Index: 22 scientists 190–191 D-Index: 13 scientists 192–193 D-Index: 21 scientists 194–195 D-Index: 12 scientists 196–197 D-Index: 12 scientists 198–199 D-Index: 14 scientists 200–201 D-Index: 15 scientists 202–203 D-Index: 13 scientists 204–205 D-Index: 10 scientists 206–207 D-Index: 8 scientists 208–209 D-Index: 4 scientists 210–211 D-Index: 12 scientists 212–213 D-Index: 11 scientists 214–215 D-Index: 10 scientists 216 D-Index: 4 scientists 217+ D-Index: 98 scientists
70 D-Index 217+

This scientist: 99 D-Index — 58th percentile

58% of scientists in this discipline score the same or lower.

The last bar groups every scientist with 217 D-Index or more.

Overview

Helen M. Colhoun is affiliated with the University of Edinburgh in the United Kingdom. Their primary field of study is Medicine, with a specific focus on Endocrinology, Diabetes and Metabolism, Genetics, Molecular Biology, Surgery, and Infectious Diseases. Their research spans several key topics including Diabetes Treatment and Management, Diabetes Management and Research, Metabolism, Diabetes and Cancer, Diabetes and associated disorders, COVID-19 Clinical Research Studies, Pancreatic function and diabetes, and Pharmacology and Obesity Treatment.

They have contributed to numerous publications in various scientific venues, with frequent contributions in Diabetes Care, bioRxiv (Cold Spring Harbor Laboratory), Diabetologia, Diabetes, and The Lancet Diabetes & Endocrinology. The volume of work in these venues highlights their engagement with the diabetes research community as well as broader metabolic and infectious disease fields.

Recent papers authored or co-authored by Helen M. Colhoun include:

  • Semaglutide and Cardiovascular Outcomes in Obesity without Diabetes, 2023, New England Journal of Medicine
  • Risk of hospital admission with coronavirus disease 2019 in healthcare workers and their households: nationwide linkage cohort study, 2020, BMJ
  • Risks of and risk factors for COVID-19 disease in people with diabetes: a cohort study of the total population of Scotland, 2020, The Lancet Diabetes & Endocrinology
  • Effect of dulaglutide on cognitive impairment in type 2 diabetes: an exploratory analysis of the REWIND trial, 2020, The Lancet Neurology
  • Semaglutide Effects on Cardiovascular Outcomes in People With Overweight or Obesity (SELECT) rationale and design, 2020, American Heart Journal

Helen M. Colhoun collaborates frequently with a number of researchers, including Paul McKeigue, Stuart J. McGurnaghan, Luke A. K. Blackbourn, David McAllister, and Sarah H. Wild. These partnerships contribute to a multidisciplinary approach within their fields of study and likely support the breadth of topics evident in their publication record.

Best Publications

  • Primary prevention of cardiovascular disease with atorvastatin in type 2 diabetes in the Collaborative Atorvastatin Diabetes Study (CARDS): multicentre randomised placebo-controlled trial

    Helen M Colhoun;D John Betteridge;Paul N Durrington;Graham A Hitman

  • Efficacy and safety of LDL-lowering therapy among men and women: Meta-analysis of individual data from 174 000 participants in 27 randomised trials

    J Fulcher;R O'Connell;M Voysey

  • Effect of interleukin-1β inhibition with canakinumab on incident lung cancer in patients with atherosclerosis: exploratory results from a randomised, double-blind, placebo-controlled trial

    Paul M Ridker;Jean G MacFadyen;Tom Thuren;Brendan M Everett

  • Problems of reporting genetic associations with complex outcomes.

    Helen M Colhoun;Paul M McKeigue;George Davey Smith

  • Association of LDL Cholesterol, Non–HDL Cholesterol, and Apolipoprotein B Levels With Risk of Cardiovascular Events Among Patients Treated With Statins: A Meta-analysis

    S. Matthijs Boekholdt;Benoit J. Arsenault;Samia Mora;Terje R. Pedersen

  • Efficacy and safety of statin therapy in older people: a meta-analysis of individual participant data from 28 randomised controlled trials

    Jane Armitage;Colin Baigent;Elizabeth Barnes;D John Betteridge

  • Very low levels of atherogenic lipoproteins and the risk for cardiovascular events: A meta-analysis of statin trials

    S. Matthijs Boekholdt;G. Kees Hovingh;Samia Mora;Benoit J. Arsenault

  • Estimated Life Expectancy in a Scottish Cohort With Type 1 Diabetes, 2008-2010

    Shona J. Livingstone;Daniel Levin;Helen C. Looker;Robert S. Lindsay

  • Use of insulin glargine and cancer incidence in Scotland: a study from the Scottish Diabetes Research Network Epidemiology Group

    H. M. Colhoun

  • Socio-economic status and blood pressure: an overview analysis

    Helen Colhoun;H. Hemingway;N. R. Poulter

  • Baseline and on-statin treatment lipoprotein(a) levels for prediction of cardiovascular events: individual patient-data meta-analysis of statin outcome trials

    Peter Willeit;Peter Willeit;Paul M Ridker;Paul J Nestel;John Simes

  • Efficacy and safety of alirocumab in high cardiovascular risk patients with inadequately controlled hypercholesterolaemia on maximally tolerated doses of statins: the ODYSSEY COMBO II randomized controlled trial

    Christopher P. Cannon;Bertrand Cariou;Dirk Blom;James M. McKenney

  • Common variants near ATM are associated with glycemic response to metformin in type 2 diabetes.

    K. Zhou;K. Zhou;C. Bellenguez;C.C.A. Spencer;A.J. Bennett

  • High risk of cardiovascular disease in patients with type 1 diabetes in the U.K.: a cohort study using the general practice research database.

    Sabita S. Soedamah-Muthu;John H. Fuller;Henrietta E. Mulnier;Veena S. Raleigh

  • Predictors of New-Onset Diabetes in Patients Treated With Atorvastatin Results From 3 Large Randomized Clinical Trials

    David D. Waters;Jennifer E. Ho;David A. DeMicco;Andrei Breazna

  • Blood pressure screening, management and control in England: results from the health survey for England 1994.

    Helen M. Colhoun;Wei Dong;Neil R. Poulter

  • Efficacy and safety of the proprotein convertase subtilisin/kexin type 9 inhibitor alirocumab among high cardiovascular risk patients on maximally tolerated statin therapy: The ODYSSEY COMBO I study.

    Dean J. Kereiakes;Jennifer G. Robinson;Christopher P. Cannon;Christelle Lorenzato

  • Risk of Cardiovascular Disease and Total Mortality in Adults with Type 1 Diabetes: Scottish Registry Linkage Study

    Shona J. Livingstone;Helen C. Looker;Eleanor J. Hothersall;Sarah H. Wild

  • Monotherapy with the PCSK9 inhibitor alirocumab versus ezetimibe in patients with hypercholesterolemia: Results of a 24 week, double-blind, randomized Phase 3 trial

    Eli M. Roth;Marja-Riitta Taskinen;Henry N. Ginsberg;John J.P. Kastelein

  • Primary prevention of cardiovascular disease with atorvastatin in type 2 diabetes in the Collaborative Atorvastatin Diabetes Study (CARDS): Multicentre randomised placebo-controlled trial

    H.M. Colhoun;D.J. Betteridge;P.N. Durrington

Frequent Co-Authors

Paul McKeigue
Paul McKeigue University of Edinburgh
Naveed Sattar
Naveed Sattar University of Glasgow
Sarah H. Wild
Sarah H. Wild University of Edinburgh
Robert Lindsay
Robert Lindsay University of Glasgow
Colin N. A. Palmer
Colin N. A. Palmer University of Dundee
Graham A. Hitman
Graham A. Hitman Queen Mary University of London
Peter Rossing
Peter Rossing University of Copenhagen
Leif Groop
Leif Groop Lund University
Paul N. Durrington
Paul N. Durrington University of Manchester

If you think any of the details on this page are incorrect, let us know.

Report an issue

We appreciate your kind effort to assist us to improve this page, it would be helpful providing us with as much detail as possible in the text box below:

Related Online Degrees & Career Pathways

For students interested in the medical field, there are several flexible online programs that can open doors to rewarding careers. Exploring him programs is a smart way to build a strong foundation in managing patient data and health records—skills that are in demand across healthcare settings.

If you’re detail-oriented and interested in the technical side of healthcare, pursuing a medical coding certification can lead to job opportunities in medical billing, insurance, and administration.

Many nursing careers now offer remote study opportunities. For those looking for an advanced clinical role on a budget, the cheapest online fnp programs provide high-quality, affordable options for becoming a Family Nurse Practitioner.

Entry-level nurses can take advantage of online nursing programs to earn their qualifications without relocating.

These online degrees offer alternative routes into healthcare and can serve as stepping stones toward further study or specialized careers in medicine.

Best Scientists Citing Helen M. Colhoun

Trending Scientists